Treatment solutions for numerous diseases that combine therapies and diagnosis are referred to as theragnosis. Theragnosis is a new concept in next-generation medicine that integrates diagnosis and treatment at the same time. Theragnostic nanoparticles (NPs) combine diagnostic and therapeutic activities into a single integrated system, allowing for simultaneous diagnosis, therapy, and therapeutic response monitoring. Noninvasive imaging methods must be included in theragnostic NPs' diagnostic function. Theragnostic encompasses a wide range of issues, including personalised medicine, pharmacogenomics, and molecular imaging, to produce efficient new targeted medicines with acceptable benefit/risk to patients and a deeper molecular understanding of how to optimise medication selection. For successful theragnosis applications, imaging agents and drugs must be given efficiently, resulting in suitable imaging signal or drug concentration in the specific disease area.
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Personalized and precision medicine (PPM) can be established as a unique healthcare model through biodesign-driven and inspired biotech, translational applications. This approach aims to ensure human healthcare, wellness, and biosafety.
Sergey Suchkov, Institute for Biotech & Global Health of RosBioTech and A.I. Evdokimov MGMSU, Russian Federation
Title : Monitoring folds localization in ultra-thin transition metal dichalcogenides using optical harmonic generation
Ahmed Raza Khan, Australian National University, Australia
Title : A systematic review of regulatory approaches for Direct- To- Consumers (DTC) genetic testing
Kavitha Palaniappan, Duke-NUS Medical School, Singapore
Title : Regulatory framework of in vitro diagnostic and artificial intelligence for precision medicine
Pei Ting Sarah Chou, Regulatory Affairs Professionals Society, Taiwan
Title : Unraveling cancer stem cell signatures in circulating tumor cells of metastatic colorectal cancer: Investigating ALDH1A1 and the repurposing potential of disulfiram via scRNA-seq
Nurul Syakima Ab Mutalib, Universiti Kebangsaan Malaysia, Malaysia